Europska Unija - češki - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - mnohočetný myelom - imunosupresiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Europska Unija - češki - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mnohočetný myelom - antineoplastická činidla - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Europska Unija - češki - EMA (European Medicines Agency)

lipomed gmbh - thalidomid - mnohočetný myelom - imunosupresiva - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.

Europska Unija - češki - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - imunostimulancia, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 20883 monohydrÁt bendamustin-hydrochloridu - koncentrát pro infuzní roztok - 25mg/ml - bendamustin

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 20883 monohydrÁt bendamustin-hydrochloridu - prášek pro koncentrát pro infuzní roztok - 2,5mg/ml - bendamustin

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi s.r.o., praha array - 3463 bendamustin-hydrochlorid - prášek pro koncentrát pro infuzní roztok - 2,5mg/ml - bendamustin

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 1760 busulfan - koncentrát pro infuzní roztok - 6mg/ml - busulfan

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 5394 karboplatina - koncentrát pro infuzní roztok - 10mg/ml - karboplatina

Češka Republika - češki - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi s.r.o., praha array - 5394 karboplatina - koncentrát pro infuzní roztok - 10mg/ml - karboplatina